2. Gene
  3. Hdac9 - histone deacetylase 9 Gene

Hdac9 - histone deacetylase 9 Gene

  • Gene
  • Protein
  • Agent
  • Ortholog
Mus musculus

Also known as HD9; HD7B; HDRP; Mitr; Hdac7b; mKIAA0744; D030072B18Rik

Gene ID: 79221 | Gene type: protein coding

About Hdac9

Chromosome 12: 34,097,579-34,967,094 reverse strand.GRCm39:CM001005.3

This gene has 12 transcripts (splice variants), 235 orthologues, 10 paralogues and is associated with 2 phenotypes. Broad expression in frontal lobe adult (RPKM 2.7), cortex adult (RPKM 1.4) and 21 other tissues.

Summary

Enables DNA-binding transcription factor binding activity and transcription corepressor activity. Acts upstream of or within several processes, including determination of adult lifespan; negative regulation of transcription by RNA polymerase II; and regulation of skeletal muscle fiber development. Part of Histone Methyltransferase complex. Is expressed in several structures, including 2-cell stage embryo; future midbrain; heart; nervous system; and trunk myotome. Orthologous to human HDAC9 (histone deacetylase 9). [provided by Alliance of Genome Resources, Apr 2022]

Hdac9 Products(2)

mRNA Protein Name
NM_001271386.1 NP_001258315.1 histone deacetylase 9 isoform 1
NM_024124.3 NP_077038.2 histone deacetylase 9 isoform 2

Hdac9 Protein Structure

ClassIIa_HDAC9_Gln-rich-N

ClassIIa_HDAC9_Gln-rich-N: cd10163 (58 - 147)

HDAC_classIIa

HDAC_classIIa: cd11681 (652 - 1029)

  • 0
  • 200
  • 400
  • 600
  • 800
  • 1000
  • 1088 a.a.
Protein Preferred Names Protein Names

histone deacetylase 9

MEF2-interacting transcription repressor MITR

histone deacetylase 7B

histone deacetylase-related protein

Related Agents

Approval
Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-13322 Pracinostat Inhibitor 99.82% Yes
Clinical Phase
Bioactive Molecules (9)
Cat. No. Product Name Effect
Purity Phase
HY-14842B Givinostat hydrochloride monohydrate Inhibitor ≥98.0% Phase 3
HY-14842 Givinostat Inhibitor 98.05% Phase 3
HY-14842A Givinostat hydrochloride Inhibitor / Phase 3
HY-15433 Quisinostat Inhibitor 98.34% Phase 2
HY-13522 Fimepinostat Inhibitor 99.95% Phase 2
HY-15433A Quisinostat dihydrochloride Inhibitor 98.28% Phase 2
HY-16012A Domatinostat Inhibitor 99.43% Phase 2
HY-16012 Domatinostat tosylate Inhibitor 99.66% Phase 2
HY-10223 CUDC-101 Inhibitor 99.19% Phase 1
Pre-clinical Phase
Bioactive Molecules (21)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-18361 TMP195 Inhibitor 99.57% Unkown
HY-18360 TMP269 Inhibitor 98.05% Unkown
HY-13428 Tubacin Inhibitor 95.50% Unkown
HY-16699 Nexturastat A Inhibitor 99.03% Unkown
HY-112719 BRD 4354 Inhibitor 99.66% Unkown
HY-115475 SW-100 Inhibitor 99.59% Unkown
HY-119939 CHDI-390576 Inhibitor 98.07% Unkown
HY-149285 NT160 Inhibitor 99.58% Unkown
HY-112719B BRD 4354 ditrifluoroacetate Inhibitor 98.06% Unkown
HY-117554 BRD9757 Inhibitor 99.75% Unkown
HY-146678 HDAC6-IN-5 Inhibitor / Unkown
HY-150109 Purinostat mesylate Inhibitor / Unkown
HY-146679 HDAC6-IN-6 Inhibitor / Unkown
HY-146684 HDAC-IN-36 Inhibitor / Unkown
HY-152225 MC2625 Inhibitor / Unkown
HY-15144B (S)-Trichostatin A Inhibitor / Unkown
HY-150595 HDAC6-IN-10 Inhibitor / Unkown
HY-149208 HDAC-IN-53 Inhibitor / Unkown
HY-152226 MC2590 Inhibitor / Unkown
HY-149283 JAK/HDAC-IN-2 Inhibitor / Unkown
HY-157740 XSJ-10 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Hdac9 NCBI NCBI:9734